Sustained Efficacy of Bimekizumab in Psoriatic Arthritis Save
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, bimekizumab (BKZ), in patients with active psoriatic arthritis and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
Here, we report long-term efficacy and safety to Week 52. 852 were randomised and 90.4% completed Week 52.
ACR50 responses at week 16 (DBRPCT portion of the trial) were:
- Placebo 10%
- BKX 44%
- ADA 46%
ACR 50 clinical efficacy was sustained out to week 52:
- BKZ: 54.5%
- ADA: 50%
PASI 90 skin responses at week 52 were:
- BKZ 71.4%
- ADA 60.3%
Safety events at week 52 were similar in all arms, with serious AEs in 6.6% of BKZ. Mucocutaneous Candida infections were seen in 7.7% of BKZ and 0.7% of ADA treated patients.
The efficacy of BKZ in bDMARD-naïve patients with PsA was sustained from Week 16 to Week 52. BKZ was well tolerated with no new safety signals observed.